<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04334759</url>
  </required_header>
  <id_info>
    <org_study_id>DREAM3R</org_study_id>
    <secondary_id>PrE0506</secondary_id>
    <secondary_id>TOGA 18/001</secondary_id>
    <secondary_id>CTC 0231</secondary_id>
    <nct_id>NCT04334759</nct_id>
  </id_info>
  <brief_title>DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma</brief_title>
  <acronym>DREAM3R</acronym>
  <official_title>DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PrECOG, LLC.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thoracic Oncology Group Australasia (TOGA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Sydney</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>PrECOG, LLC.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with malignant pleural mesothelioma (MPM) that cannot be surgically removed will&#xD;
      receive first-line treatment with standard chemotherapy of cisplatin or carboplatin and&#xD;
      pemetrexed. Two-thirds of the participants in the study will be randomly assigned to also&#xD;
      receive a new treatment called durvalumab.&#xD;
&#xD;
      Durvalumab is an antibody (a type of human protein) that works by blocking a body substance&#xD;
      called Programmed Death-Ligand 1 (PD-L1). Blocking PD-L1 helps the body's immune system&#xD;
      attack cancer cells. Research has shown that durvalumab can slow tumor growth and shrink&#xD;
      tumors in some people with cancer. Previous studies of combining durvalumab and chemotherapy&#xD;
      showed that this combination is active in advanced mesothelioma.&#xD;
&#xD;
      The purpose of this study is to see whether adding durvalumab to standard chemotherapy will&#xD;
      improve overall survival (OS) in patients with MPM.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mesothelioma is a malignant tumor of the mesothelial surfaces primarily arising in the&#xD;
      thoracic pleura. In the United Kingdom and USA the expected number of cases in the next few&#xD;
      decades are 65,000 and 85,000, respectively. Once diagnosed, this disease is rarely cured&#xD;
      with a median survival of less than a year.&#xD;
&#xD;
      This is an International, Open-Label, Multi-center, Phase III study. Patients will be&#xD;
      randomized 2:1 to receive durvalumab with standard chemotherapy or to receive standard&#xD;
      chemotherapy alone.&#xD;
&#xD;
      Arm A: Durvalumab every 3 weeks + standard chemotherapy (Cisplatin or Carboplatin every 3&#xD;
      weeks + Pemetrexed every 3 weeks) for 4 to 6 cycles, followed by Durvalumab every 4 weeks.&#xD;
&#xD;
      Arm B: Standard chemotherapy (Cisplatin or Carboplatin every 3 weeks + Pemetrexed every 3&#xD;
      weeks) for 4 to 6 cycles followed by observation.&#xD;
&#xD;
      Treatment with durvalumab in Arm A will continued until disease progression, unacceptable&#xD;
      toxicity or patient withdrawal.&#xD;
&#xD;
      Tumor assessments and Quality of Life forms will be performed at baseline, then at weeks 6,&#xD;
      12, 18, 26, 34, 42, 50 and then every 12 weeks until disease progression.&#xD;
&#xD;
      Mandatory pre-treatment tumor tissue sample (i.e., obtained during a previous procedure or&#xD;
      biopsy) for research will also be required. Blood samples for research at baseline, day 1 of&#xD;
      cycle 2, and day 1 of cycle 3 will be done.&#xD;
&#xD;
      The study is being led jointly by PrECOG as the US sponsor and University of Sydney as the&#xD;
      international sponsor&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 18, 2021</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">April 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>First-line chemotherapy with cisplatin or carboplatin and pemetrexed +/- durvalumab.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Minimum follow-up is 24 months after randomisation.</time_frame>
    <description>Defined as the time from randomisation to the date of death due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Performed at baseline, then at weeks 6, 12, 18, 26, 34, 42, 50 and then every 12 weeks until disease progression (minimum follow-up is 24 months after randomisation).</time_frame>
    <description>Defined as the interval from date of randomisation to the date of first evidence of disease progression or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Tumour Response Rate (OTRR)</measure>
    <time_frame>Performed at baseline, then at weeks 6, 12, 18, 26, 34, 42, 50 and then every 12 weeks until disease progression (minimum follow-up is 24 months after randomisation).</time_frame>
    <description>Percentage of participants with either Complete Response (CR) or Partial Response (PR) assessed according to modified Response Criteria in Solid Tumors (RECIST) 1.1 for response in malignant pleural mesothelioma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Classify and grade participants adverse events as assessed by CTCAE V5.0</measure>
    <time_frame>90 days after last dose of durvalumab or 30 days after last dose of chemotherapy, whichever is longer.</time_frame>
    <description>Classify and grade participants abnormal laboratory values and/or adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-Related Quality of Life (QOL): QLQ-C30</measure>
    <time_frame>Performed at baseline, then at weeks 6, 12, 18, 26, 34, 42, 50 and then every 12 weeks until disease progression (minimum follow-up is 24 months after randomisation).</time_frame>
    <description>European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30), Importance of QOL issues assessed using a four-point scale (1 = not at all, 4 = very much).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-Related QOL: LC29</measure>
    <time_frame>Performed at baseline, then at weeks 6, 12, 18, 26, 34, 42, 50 and then every 12 weeks until disease progression (minimum follow-up is 24 months after randomisation).</time_frame>
    <description>EORTC Quality of Life Lung Cancer Module (QLQ-LC29), Importance of QOL issues assessed using a four-point scale (1 = not at all, 4 = very much).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-Related QOL: EQ-5D-5L</measure>
    <time_frame>Performed at baseline, then at weeks 6, 12, 18, 26, 34, 42, 50 and then every 12 weeks until disease progression (minimum follow-up is 24 months after randomisation).</time_frame>
    <description>Euro-Quality of Life (EuroQoL) 5 dimension 5 level (EQ-5D-5L) questionnaire, comprising of 5 questions with a score from 1 (no problem) to 5 (extreme problem) and a visual analog scale from 0 (worst) to 100 (best).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Care Usage Costs: Hospitalization</measure>
    <time_frame>Minimum follow-up is 24 months after randomisation.</time_frame>
    <description>Australian Sites Only: Hospitalization costs calculated by applying Australian unit costs to Australian Refined Diagnostic Related Groups (AR DRG) costs for hospitalizations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Care Usage Costs: Scheduled Visits to Health Professionals</measure>
    <time_frame>Minimum follow-up is 24 months after randomisation.</time_frame>
    <description>Australian Sites Only: Scheduled costs for visits to health professionals collected via Medical Benefits Schedule (MBS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Care Usage Costs: Medications</measure>
    <time_frame>Minimum follow-up is 24 months after randomisation.</time_frame>
    <description>Australian Sites Only: Scheduled costs for medications collected via the Pharmaceutical Benefits Schedule (PBS).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Mesothelioma</condition>
  <condition>Pleural Mesothelioma</condition>
  <condition>Malignant Pleural Mesothelioma</condition>
  <arm_group>
    <arm_group_label>Arm A: Durvalumab + Chemotherapy, then Durvalumab Maintenance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Durvalumab + Standard Chemotherapy for 4 to 6 cycles, followed by Maintenance with Durvalumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Chemotherapy, then Observation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard Chemotherapy for 4 to 6 cycles, followed by Observation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>Durvalumab 1500 milligrams (mg) intravenous (IV) every 3 weeks + Cisplatin 75 mg/m² or Carboplatin AUC 5 IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks for 4 to 6 cycles, followed by maintenance with Durvalumab 1500 mg IV every 4 weeks</description>
    <arm_group_label>Arm A: Durvalumab + Chemotherapy, then Durvalumab Maintenance</arm_group_label>
    <other_name>MEDI4736</other_name>
    <other_name>Imfinzi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard Chemotherapy</intervention_name>
    <description>Cisplatin 75 mg/m² or Carboplatin AUC 5 IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks) for 4 to 6 cycles, followed by Observation</description>
    <arm_group_label>Arm B: Chemotherapy, then Observation</arm_group_label>
    <other_name>Cisplatin or Carboplatin and Pemetrexed</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults (18 years or over) with a histological diagnosis of malignant pleural&#xD;
             mesothelioma that is not amenable to curative surgical resection. Histological&#xD;
             diagnosis requires tumour tissue from an open biopsy, or a core biopsy with a needle&#xD;
             of 19 gauge or wider.&#xD;
&#xD;
          -  Measurable disease as per modified RECIST 1.1 (mRECIST 1.1) criteria for assessment of&#xD;
             response in malignant pleural mesothelioma, without prior radiotherapy to these sites.&#xD;
&#xD;
          -  Body weight &gt;30 kg,&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
          -  Tumour tissue (Formalin-Fixed Paraffin-Embedded [FFPE]) available from diagnostic&#xD;
             biopsy for PD-L1 testing and other correlative biomarker testing at a central&#xD;
             laboratory.&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks.&#xD;
&#xD;
          -  Adequate blood tests (done within 14 days prior to randomisation) and with values&#xD;
             within the ranges specified below. Blood transfusions are permissible if completed at&#xD;
             least 7 days prior to treatment start.&#xD;
&#xD;
               -  Haemoglobin ≥ 9.0 g/L&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1.5 x 10^9/L&#xD;
&#xD;
               -  Platelets ≥ 100 x 10^9/L&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (except participants with&#xD;
                  Gilbert's Syndrome, who are eligible with bilirubin ≤ 2.5 ULN)&#xD;
&#xD;
               -  Alanine transaminase ≤ 2.5 x upper limit of normal (ULN), unless liver metastases&#xD;
                  or invasion are present, in which case it must be ≤ 5 x ULN&#xD;
&#xD;
               -  Aspartate aminotransferase ≤ 2.5 x ULN, unless liver metastases or invasion are&#xD;
                  present, in which case it must be ≤ 5 x ULN&#xD;
&#xD;
               -  Creatinine clearance (CrCl) ≥ 45 mL/min (Cockcroft-Gault formula). NOTE:&#xD;
                  Carboplatin AUC 5 must be the initial platinum agent of choice in patients with&#xD;
                  creatinine Cl &lt;60 mL/min but ≥ 45 mL/min, or those with clinically reported&#xD;
                  hearing loss.&#xD;
&#xD;
          -  Patient consent must be appropriately obtained in accordance with applicable local and&#xD;
             regulatory requirements. Each patient or legal representative must sign a consent form&#xD;
             prior to enrolment in the trial to document their willingness to participate.&#xD;
&#xD;
          -  Willing and able to comply with all study requirements, including treatment, timing&#xD;
             and/or nature of required assessments.&#xD;
&#xD;
          -  Women of childbearing potential must use a reliable means of contraception during&#xD;
             treatment and for at least 90 days thereafter. Breastfeeding is not permissible during&#xD;
             or for at least 90 days after the final study treatment. Men must have been surgically&#xD;
             sterilised or use a barrier method of contraception if they are sexually active with a&#xD;
             woman of child bearing potential.&#xD;
&#xD;
          -  Evidence of post-menopausal status or negative serum pregnancy test for female&#xD;
             pre-menopausal patients. Women will be considered post-menopausal if they have been&#xD;
             amenorrheic for 12 months without an alternative medical cause.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior chemotherapy or other systemic anti-cancer or immunotherapy for MPM.&#xD;
&#xD;
          -  Diagnosis based only on cytology or aspiration biopsy with a needle narrower than 19&#xD;
             gauge.&#xD;
&#xD;
          -  Active or prior documented autoimmune or inflammatory disorders (including&#xD;
             inflammatory bowel disease [e.g. colitis or Crohn's disease], diverticulitis [with the&#xD;
             exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or&#xD;
             Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid&#xD;
             arthritis, hypophysitis, uveitis, etc.]). The following are exceptions to this&#xD;
             criterion:&#xD;
&#xD;
               1. Patients with vitiligo or alopecia&#xD;
&#xD;
               2. Patients with hypothyroidism (e.g. following Hashimoto syndrome) stable on&#xD;
                  hormone replacement&#xD;
&#xD;
               3. Any chronic skin condition that does not require systemic therapy&#xD;
&#xD;
               4. Patients without active disease in the last 5 years may be included&#xD;
&#xD;
               5. Patients with celiac disease controlled by diet alone&#xD;
&#xD;
          -  Any condition requiring systemic treatment with either corticosteroids (&gt;10 mg daily&#xD;
             prednisone or equivalent dose of an alternative corticosteroid) or other&#xD;
             immunosuppressive medications within 28 days of durvalumab administration. Intranasal,&#xD;
             inhaled or topical steroids or local steroid injections (e.g. intra-articular&#xD;
             injection) are permitted in the absence of active autoimmune disease. Standard steroid&#xD;
             premedication given prior to chemotherapy or as prophylaxis for imaging contrast&#xD;
             allergy should not be counted for this criterion.&#xD;
&#xD;
          -  Participants with symptomatic or uncontrolled brain metastases or leptomeningeal&#xD;
             disease are excluded.&#xD;
&#xD;
          -  Prior therapy with an anti-PD-1, anti-PD-L1 (including durvalumab), anti-PD-L2,&#xD;
             anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T cell&#xD;
             co-stimulation or immune checkpoint pathways.&#xD;
&#xD;
          -  Current treatment or treatment within the last 12 months with any investigational&#xD;
             anti-cancer products.&#xD;
&#xD;
          -  Concurrent enrolment in another clinical study testing an anticancer treatment.&#xD;
&#xD;
          -  Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 msec&#xD;
             in screening ECG measured using standard institutional method or history of familial&#xD;
             long QT syndrome.&#xD;
&#xD;
          -  Major surgical procedure (as defined by the Investigator) within 28 days prior to the&#xD;
             first dose of study treatment on protocol. Note: Local surgery of isolated lesions for&#xD;
             palliative intent is acceptable. Limited pleural biopsy procedures do not apply.&#xD;
&#xD;
          -  No other malignancy that requires active treatment. Participants with a past history&#xD;
             of adequately treated carcinoma in situ, non-melanoma skin cancer or lentigo maligna&#xD;
             without evidence of disease or superficial transitional cell carcinoma of the bladder&#xD;
             are eligible.&#xD;
&#xD;
          -  Hearing loss or peripheral neuropathy considered by the investigators to&#xD;
             contraindicate administration of either cisplatin, carboplatin or pemetrexed.&#xD;
&#xD;
          -  History of allergy or hypersensitivity to investigational product, cisplatin,&#xD;
             carboplatin, pemetrexed or any excipient.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive cardiac failure, uncontrolled hypertension, unstable&#xD;
             angina pectoris, cardiac arrhythmia, interstitial lung disease, active peptic ulcer&#xD;
             disease or gastritis, serious chronic gastrointestinal conditions associated with&#xD;
             diarrhoea, active bleeding diatheses.&#xD;
&#xD;
          -  Hepatitis B, hepatitis C or human immunodeficiency virus (HIV). Exceptions include&#xD;
             past or resolved Hepatitis B (defined as the presence of hepatitis B core antibody&#xD;
             [anti-HBc] and absence of HBsAg) and patients positive for hepatitis C (HCV) antibody&#xD;
             if polymerase chain reaction is negative for HCV RNA. HIV testing is not required in&#xD;
             absence of clinical suspicion of HIV.&#xD;
&#xD;
          -  Known history of primary immunodeficiency, allogeneic organ transplant, pneumonitis or&#xD;
             active tuberculosis.&#xD;
&#xD;
          -  Receipt of live attenuated vaccination within 30 days prior to enrolment or within 30&#xD;
             days of receiving durvalumab.&#xD;
&#xD;
          -  Specific comorbidities or conditions or concomitant medications which may interact&#xD;
             with the investigational product(s).&#xD;
&#xD;
          -  Any condition that, in the opinion of the investigator, would interfere with&#xD;
             evaluation of study treatment or interpretation of patient safety or study results.&#xD;
&#xD;
          -  Serious medical or psychiatric conditions or social situation that might limit&#xD;
             compliance with study requirements, substantially increase risk of incurring adverse&#xD;
             events or compromise the ability of the patient to give written informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Forde, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anna Nowak, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Faculty of Health and Medical Sciences University of Western Australia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deb Riordan- US Sites, BSN, RN</last_name>
    <phone>267-271-4884</phone>
    <email>DREAM3R@precogllc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ailsa Langford- International Sites</last_name>
    <phone>61-2-9562-5000</phone>
    <email>DREAM3R.study@sydney.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lyudmila Bazhenova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>18054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tawee Tanvetyanon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Conor Steuer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hedy Kindler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Patrick Forde, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massaschusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ibiayi Dagogo-Jack, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Kwiatkowski, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Angel Qin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Metro Minnesota Community Oncology Research Consortium</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Arkadiusz Dudek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Majorie Zauderer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>James Stevenson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State Cancer Institute</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Patrick MA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Cener at Penn Presbyterian Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Melina Marmarelis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hossein Borghaei, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegheny Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gene Finley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Erin Gillaspie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Daniel Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Blacktown Hospital</name>
      <address>
        <city>Blacktown</city>
        <state>New South Wales</state>
        <zip>2148</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Adnan Nagrial, MBBS, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coffs Harbour Health Campus</name>
      <address>
        <city>Coffs Harbour</city>
        <state>New South Wales</state>
        <zip>2450</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Karen Briscoe, MBBS, FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gosford Hospital</name>
      <address>
        <city>Gosford</city>
        <state>New South Wales</state>
        <zip>2250</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Matthew Chan, MBBS, FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wyong Hospital</name>
      <address>
        <city>Hamlyn Terrace</city>
        <state>New South Wales</state>
        <zip>2259</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Matthew Chan, MBBS, FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nepean Hospital</name>
      <address>
        <city>Kingswood</city>
        <state>New South Wales</state>
        <zip>2747</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Deme Karikios, MBBS, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Victoria Bray, MBBS PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orange Health Service</name>
      <address>
        <city>Orange</city>
        <state>New South Wales</state>
        <zip>2800</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Robert Zielinski, MBBS FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northern Cancer Institute (GenesisCare)</name>
      <address>
        <city>Saint Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nick Pavlakis, MMed, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Calvary Mater Newcastle</name>
      <address>
        <city>Waratah</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hiren Mandaliya, MBBS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rina Hui, MBBS, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icon Cancer Care Wesley</name>
      <address>
        <city>Auchenflower</city>
        <state>Queensland</state>
        <zip>4066</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Adam Stirling, MBBS FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunshine Coast University Hospital</name>
      <address>
        <city>Birtinya</city>
        <state>Queensland</state>
        <zip>4575</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bryan Chan, BPharm, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icon Cancer Care Chermside</name>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Adam Stirling, MBBS FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Prince Charles Hospital</name>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Brett Hughes, MBBS, FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icon Cancer Care South Brisbane</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Adam Stirling, MBBS FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kenneth O'Byrne, MB, BCh, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Shawgi Sukumaran, MBBS, DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Queen Elizabeth Hospital</name>
      <address>
        <city>Woodville South</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rachel Roberts-Thomson, MBBS, FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Hobart Hospital</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rebecca Tay, MBBS FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Launceston General Hospital</name>
      <address>
        <city>Launceston</city>
        <state>Tasmania</state>
        <zip>7250</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Axel Durieux, MBBS FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monash Health</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Muhammad Alamgeer, MBBS FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peninsula &amp; South Eastern Haematology and Oncology Group</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vinod Ganju, MBBS FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paul Mitchell, MBBS FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thomas John, MBBS, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Epworth HealthCare - Richmond</name>
      <address>
        <city>Richmond</city>
        <state>Victoria</state>
        <zip>3121</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ross Jennens, MBBS FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunshine Hospital (Western Health)</name>
      <address>
        <city>Saint Albans</city>
        <state>Victoria</state>
        <zip>3021</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Suzanne Kosmider, MBBS FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Goulburn Valley Health</name>
      <address>
        <city>Shepparton</city>
        <state>Victoria</state>
        <zip>3630</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Myron Klevansky, MBBS, FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital (SCGH)</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anna Nowak, MBBS, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Grafton</city>
        <state>Auckland</state>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Aileen Ludlow, MBBS FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 2, 2020</study_first_submitted>
  <study_first_submitted_qc>April 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2020</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Unresectable Mesothelioma</keyword>
  <keyword>Durvalumab</keyword>
  <keyword>Anti-Programmed Death-Ligand 1 Antibody</keyword>
  <keyword>Immune Checkpoint Inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Durvalumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data is proprietary</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

